Page 181 - Read Online

Zheng et al. Hepatoma Res 2018;4:17 I http://dx.doi.org/10.20517/2394-5079.2018.08 Page 7 of 8

38. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su LJ. Prevalence and significance of hepatitis B virus
(HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001;33:277-86.
39. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular
carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101:1066-82.
40. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of
hepatitis B virus. Lancet 1990;336:325-9.
41. Biswas S, Candotti D, Allain JP. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to
occult hepatitis B virus infection. J Virol 2013;87:7882-92.
42. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G, Raimondo G. Pre-S2
defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 1997;26:495-9.
43. Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B
infection leads to virus retention and misassembly. Gastroenterology 1997;113:1976-82.
44. Li F, Li X, Yan T, Liu Y, Cheng Y, Xu Z, Shao Q, Liao H, Huang P, Li J, Chen GF, Xu D. The preS deletion of hepatitis B virus (HBV)
is associated with liver fibrosis progression in patients with chronic HBV infection. Hepatol Int 2018;12:107-17.
45. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su LJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection
contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003;163:2441-9.
46. Fan YF, Lu CC, Chang YC, Chang TT, Lin PW, Lei HY, Su LJ. Identification of a pre-S2 mutant in hepatocytes expressing a novel
marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15:519-28.
47. Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su LJ. A clustered ground-glass hepatocyte pattern represents
a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer 2011;117:2951-60.
48. Huang SF, Chen YT, Lee WC, Chang IC, Chiu YT, Chang Y, Tu HC, Yuh CH, Matsuura I, Shih LY, Lai MW, Wu HD, Chen MF, Yeh
CT. Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular
carcinoma. PLoS One 2014;9:e89753.
49. Li ZQ, Linghu E, Jun W, Cheng J. Screening of hepatocyte proteins binding with C-terminally truncated surface antigen middle protein
of hepatitis B virus (MHBst167) by a yeast two-hybrid system. Mol Med Rep 2014;10:1259-63.
50. Siburian MD, Suriapranata IM, Wanandi SI. Pre-S2 start codon mutation of hepatitis B virus subgenotype B3 effects on NF-kappaB
expression and activation in Huh7 cell lines. Viral Immunol 2018; doi: 10.1089/vim.2017.0158.
51. Huy TT, Ushijima H, Win KM, Luengrojanakul P, Shrestha PK, Zhong ZH, Smirnov AV, Taltavull TC, Sata T, Abe K. High prevalence
of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol
2003;41:5449-55.
52. Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, Chen BF. Fine mapping of hepatitis B virus pre-S deletion and its association with
hepatocellular carcinoma. Liver Int 2012;32:1373-81.
53. Zhang D, Dong P, Zhang K, Deng L, Bach C, Chen W, Li F, Protzer U, Ding H, Zeng C. Whole genome HBV deletion profiles and the
accumulation of preS deletion mutant during antiviral treatment. BMC Microbiol 2012;12:307.
54. Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Huang J, Wang XY, Harrison TJ. Hepatitis B virus pre-S deletion
mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J General Virol 2008;89:2882-90.
55. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis
B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007;133:1466-74.
56. Huang HP, Hsu HY, Chen CL, Ni YH, Wang HY, Tsuei DJ, Chiang CL, Tsai YC, Chen HL, Chang MH. Pre-S2 deletions of hepatitis B
virus and hepatocellular carcinoma in children. Pediatr Res 2010;67:90-4.
57. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su LJ. Pre-S2 deletion mutants of hepatitis B virus could
have an important role in hepatocarcinogenesis in Asian children. Cancer Sci 2009;100:2249-54.
58. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2
signaling in transgenic mice. EMBO J 2002;21:525-35.
59. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3’ truncations within a
defined region of the S gene. J Virol 1992;66:5284-9.
60. Caselmann WH. Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of
hepatocarcinogenesis. J Hepatol 1995;22:34-7.
61. Liang X, Du J, Liu Y, Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, Chen YH, Sun W. The hepatitis B virus protein MHBs(t)
sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 2007;12:1827-36.
62. Zhang X, Gao L, Liang X, Guo M, Wang R, Pan Y, Liu P, Zhang F, Guo C, Zhu F, Qu C, Ma C. HBV preS2 transactivates FOXP3
expression in malignant hepatocytes. Liver Int 2015;35:1087-94.
63. Luan F, Liu B, Zhang J, Cheng S, Zhang B, Wang Y. Correlation between HBV protein preS2 and tumor markers of hepatocellular
carcinoma. Pathol Res Pract 2017;213:1037-42.
64. Fu X, Tan D, Hou Z, Hu Z, Liu G. MiR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the
3’-UTR region of CyclinD1. Int J Mol Sci 2012;13:8514-39.
65. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells
to sorafenib by targeting hypoxia-induced factor 1alpha. PLoS One 2014;9:e115565.
66. Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B, Bai F, Gao L, Ma C. HBV preS2 promotes the expression of TAZ via miRNA-338-3p
to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget 2015;6:29048-59.